FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322773917> ?p ?o ?g. }

• W4322773917 endingPage "07" @default.
• W4322773917 startingPage "P2" @default.
• W4322773917 abstract "Abstract Background: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine have shown clinically and statistically meaningful progression-free survival and overall survival benefits with acceptable tolerability in patients with HER2-positive metastatic breast cancer in phase 3 trials. In this study, we assessed the efficacy and safety of neoadjuvant pyrotinib plus trastuzumab, taxanes and platinum in women with HER2-positive early or locally advanced breast cancer. Methods: In this multicenter, single-arm, phase II trial (ChiCTR2000039286), treatment-naive patients with early or locally advanced (T2-3, N0-3, M0) breast cancer received pyrotinib 400 mg once daily, plus trastuzumab (8 mg/kg loading dose and 6 mg/kg maintenance dose), docetaxel (75 mg/m2) or nab-paclitaxel (125 mg/m2), and carboplatin (AUC=5-7) on day 1 of each 21-day cycle for 6 cycles before surgery. All patients also received 1-year adjuvant pyrotinib combined with trastuzumab after surgery. The primary endpoint of the study was total pathological complete response (tpCR, ypT0/is ypN0) rate. The secondary endpoints were breast pathological complete response (bpCR) rate, objective response rate, adverse events (AEs) and invasive disease-free survival. Results: Between October 2020 and March 2022, a total of 35 patients were enrolled from 7 sites. By the data cut-off date on June 29, 2022, two patients withdrew from the study, and one received other anti-tumor therapies. Thirty-two patients received neoadjuvant therapy and surgery (modified intention-to-treat [mITT] population), and 30 of whom completed the 6-cycle neoadjuvant therapy (per-protocol [PP] population). The local pathologist-assessed tpCR rate was 59.4% (19/32) and 60.0% (18/30) in the mITT and PP populations, and bpCR rate was 65.6% (21/32) and 66.7% (20/30) in the mITT and PP populations, respectively. The tpCR rate was 68.8% (11/16) among patients with hormone receptor-negative disease and 50.0% (8/16) among those with hormone receptor-positive disease in the mITT population. Of 30 patients with preoperative imaging assessments, 26 (86.7%) achieved an objective response. Treatment-related AEs (TRAEs) were reported in 34 (97.1%) of 35 patients, with the most common being diarrhea (82.9%) and platelet decreased (48.6%). The most common grade ≥3 TRAEs were diarrhea (25.7%), platelet decreased (8.6%), neutropenia (8.6%), vomiting (5.7%), and alanine aminotransferase increased (5.7%). No grade 4 or 5 diarrhea events occurred. Conclusions: This study showed similar efficacy with previous reports, neoadjuvant pyrotinib plus trastuzumab-based chemotherapy exhibits promising efficacy and manageable toxicity in patients with HER2-positive early or locally advanced breast cancer. Citation Format: Hao Zhou, Lei Wang, Lei Wang, Zhaoji Guo. Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P2-01-07." @default.
• W4322773917 created "2023-03-03" @default.
• W4322773917 creator A5020390525 @default.
• W4322773917 creator A5027510488 @default.
• W4322773917 creator A5073216396 @default.
• W4322773917 date "2023-03-01" @default.
• W4322773917 modified "2023-10-16" @default.
• W4322773917 title "Abstract P2-01-07: Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial" @default.
• W4322773917 doi "https://doi.org/10.1158/1538-7445.sabcs22-p2-01-07" @default.
• W4322773917 hasPublicationYear "2023" @default.
• W4322773917 type Work @default.
• W4322773917 citedByCount "0" @default.
• W4322773917 crossrefType "journal-article" @default.
• W4322773917 hasAuthorship W4322773917A5020390525 @default.
• W4322773917 hasAuthorship W4322773917A5027510488 @default.
• W4322773917 hasAuthorship W4322773917A5073216396 @default.
• W4322773917 hasConcept C121608353 @default.
• W4322773917 hasConcept C126322002 @default.
• W4322773917 hasConcept C141071460 @default.
• W4322773917 hasConcept C143998085 @default.
• W4322773917 hasConcept C197934379 @default.
• W4322773917 hasConcept C203092338 @default.
• W4322773917 hasConcept C2776694085 @default.
• W4322773917 hasConcept C2778239845 @default.
• W4322773917 hasConcept C2778292576 @default.
• W4322773917 hasConcept C2778375690 @default.
• W4322773917 hasConcept C2779786085 @default.
• W4322773917 hasConcept C2781190966 @default.
• W4322773917 hasConcept C2781451048 @default.
• W4322773917 hasConcept C2908647359 @default.
• W4322773917 hasConcept C530470458 @default.
• W4322773917 hasConcept C535046627 @default.
• W4322773917 hasConcept C71924100 @default.
• W4322773917 hasConcept C99454951 @default.
• W4322773917 hasConceptScore W4322773917C121608353 @default.
• W4322773917 hasConceptScore W4322773917C126322002 @default.
• W4322773917 hasConceptScore W4322773917C141071460 @default.
• W4322773917 hasConceptScore W4322773917C143998085 @default.
• W4322773917 hasConceptScore W4322773917C197934379 @default.
• W4322773917 hasConceptScore W4322773917C203092338 @default.
• W4322773917 hasConceptScore W4322773917C2776694085 @default.
• W4322773917 hasConceptScore W4322773917C2778239845 @default.
• W4322773917 hasConceptScore W4322773917C2778292576 @default.
• W4322773917 hasConceptScore W4322773917C2778375690 @default.
• W4322773917 hasConceptScore W4322773917C2779786085 @default.
• W4322773917 hasConceptScore W4322773917C2781190966 @default.
• W4322773917 hasConceptScore W4322773917C2781451048 @default.
• W4322773917 hasConceptScore W4322773917C2908647359 @default.
• W4322773917 hasConceptScore W4322773917C530470458 @default.
• W4322773917 hasConceptScore W4322773917C535046627 @default.
• W4322773917 hasConceptScore W4322773917C71924100 @default.
• W4322773917 hasConceptScore W4322773917C99454951 @default.
• W4322773917 hasIssue "5_Supplement" @default.
• W4322773917 hasLocation W43227739171 @default.
• W4322773917 hasOpenAccess W4322773917 @default.
• W4322773917 hasPrimaryLocation W43227739171 @default.
• W4322773917 hasRelatedWork W1967391695 @default.
• W4322773917 hasRelatedWork W2004818507 @default.
• W4322773917 hasRelatedWork W2066747782 @default.
• W4322773917 hasRelatedWork W2091007248 @default.
• W4322773917 hasRelatedWork W2277576025 @default.
• W4322773917 hasRelatedWork W2561002551 @default.
• W4322773917 hasRelatedWork W2727568273 @default.
• W4322773917 hasRelatedWork W2901487801 @default.
• W4322773917 hasRelatedWork W3004430295 @default.
• W4322773917 hasRelatedWork W4379798874 @default.
• W4322773917 hasVolume "83" @default.
• W4322773917 isParatext "false" @default.
• W4322773917 isRetracted "false" @default.
• W4322773917 workType "article" @default.